Understanding how a bacterial protein that influences the risk of stomach cancer is produced could guide new strategies for treatment.

For much of her career, Angelika Amon, PhD, recipient of the 2018 Vanderbilt Prize in Biomedical Science, has pursued a mystery with life-or-death consequences.

A Vanderbilt initiative to develop predictive imaging technologies that clinicians can use to better match patients with personalized care has received National Cancer Institute (NCI) funding.

Around two-thirds of patients treated for breast cancer will have had hormone-sensitive tumors and, after their initial treatment, will be advised to undergo hormone therapy for five to 10 years to prevent recurrence.

Angelika Amon, PhD, recipient of the 2018 Vanderbilt Prize in Biomedical Science, will deliver her Vanderbilt Prize lecture at 4 p.m. Thursday, Jan. 31, in 208 Light Hall.

A large-scale study conducted among East Asians and led by Vanderbilt researchers has identified multiple, previously unknown genetic risk factors for colorectal cancer.

GE Healthcare and Vanderbilt University Medical Center (VUMC) today announced a five-year partnership to enable safer and more precise cancer immunotherapies.